{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:14:06Z","timestamp":1791220446165,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER2) over-expression in breast cancer is associated with aggressive tumor behavior and predicts response to targeted therapy. Accurate HER2 result is paramount for optimal patient management. However, routine HER2 immunohistochemistry (IHC) testing are subjected to intra- and inter-laboratory variability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aims to determine inter-laboratory variation in HER2 IHC testing through a slide-exchange program between five main reference laboratories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A total of 20 breast carcinoma cases with different known HER2 expression and gene status were selected by the central laboratory in five testing rounds. Three unstained tissue sections from each case were sent to participating laboratories, which immunostained and interpreted the HER2 immunohistochemistry result. One of the stained slides was sent to one designated participating laboratory for evaluation. Results were analyzed by the central laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A complete concordance was achieved in six IHC-positive and six IHC-negative cases, its gene status of which was confirmed by in-situ-hybridization (ISH) study. The discordant results were observed in six equivocal cases, one negative case and one positive case with a concordance rate of 50\u201388.3%. Interestingly, the negative discordant case actually displays tumor heterogeneity. Good inter-observer agreement was achieved for all participating laboratories (k = 0.713-1.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Standardization of HER2 testing method is important to achieve optimum inter-laboratory concordance. Discordant results were seen mainly in equivocal cases. Intra-tumoral heterogeneity may impact the final HER2 IHC scoring. The continuous quality evaluation is therefore paramount to achieve reliable HER2 results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_983_20","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:19:44Z","timestamp":1717042784000},"page":"677-682","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["HER2 testing by immunohistochemistry in breast cancer"],"prefix":"10.4103","volume":"64","author":[{"given":"Suria Hayati","family":"Md Pauzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noraidah","family":"Masir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azyani","family":"Yahaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazarina","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Maya Sabrina","family":"Tizen Laim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muatamarulain","family":"Mustangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azimatun Noor","family":"Aizudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arni","family":"Talib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kean-Hooi","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norain","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline Wong","family":"Oy-Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathmanathan","family":"Rajadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20240829","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1309\/AJCP5UUMFMA5ZKII","article-title":"What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard","volume":"130","author":"Umemura","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"R2-10-20240829","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/modpathol.3800774","article-title":"Standardization of HER2 testing: Results of an international proficiency-testing ring study","volume":"20","author":"Dowsett","year":"2007","journal-title":"Mod Pathol"},{"key":"R3-10-20240829","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R4-10-20240829","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr1776","article-title":"Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: An international validation ring study","volume":"9","author":"van de Vijver","year":"2007","journal-title":"Breast Cancer Res"},{"key":"R5-10-20240829","first-page":"133","article-title":"A comparison study of HER2 protein overexpression and its gene status in breast cancer","volume":"41","author":"Md Pauzi","year":"2019","journal-title":"Malays J Pathol"},{"key":"R6-10-20240829","first-page":"121","article-title":"Intraoperative frozen section sentinel lymph node assessment in breast cancer: A tertiary institution experience","volume":"40","author":"Lai","year":"2018","journal-title":"Malays J Pathol"},{"key":"R7-10-20240829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R8-10-20240829","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R9-10-20240829","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry","volume":"18","author":"Pauletti","year":"2000","journal-title":"J Clin Oncol"},{"key":"R10-10-20240829","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"R11-10-20240829","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1309\/980M-E24R-V19K-595D","article-title":"HER-2\/neu protein expression in breast cancer evaluated by immunohistochemistry: A study of interlaboratory agreement","volume":"113","author":"Jacobs","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R12-10-20240829","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/modpathol.3880440","article-title":"HER-2\/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization","volume":"14","author":"Thomson","year":"2001","journal-title":"Mod Pathol"},{"key":"R13-10-20240829","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+or 2+","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"R14-10-20240829","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1016146130767","article-title":"Evaluation of HER-2\/NEU protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2\/NEU testing","volume":"74","author":"Gancberg","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"R15-10-20240829","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/01.LAB.0000032371.16521.40","article-title":"Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer","volume":"82","author":"Gl\u00f6ckner","year":"2002","journal-title":"Lab Invest"},{"key":"R16-10-20240829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","article-title":"Intratumoral heterogeneity of HER2\/neu in breast cancer\u2014A rare event","volume":"13","author":"Hanna","year":"2007","journal-title":"Breast J"},{"key":"R17-10-20240829","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2004.04.158","article-title":"HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis","volume":"22","author":"Elkin","year":"2004","journal-title":"J Clin Oncol"},{"key":"R18-10-20240829","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1600-0463.2012.02929.x","article-title":"Assessing HER 2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer","volume":"120","author":"Hillig","year":"2012","journal-title":"APMIS"},{"key":"R19-10-20240829","first-page":"16","article-title":"The Detection of HER2 gene amplification in breast cancer by upQMPSF","volume":"1","author":"Azrak","year":"2017","journal-title":"J Genet Genet Eng"},{"key":"R20-10-20240829","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jcp.2006.043562","article-title":"Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: Assessment of test sensitivity and impact of chromosome 17 polysomy","volume":"61","author":"Hofmann","year":"2008","journal-title":"J Clin Pathol"},{"key":"R21-10-20240829","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jnci\/94.11.852","article-title":"Real-world performance of HER2 testing\u2014national surgical adjuvant breast and bowel project experience","volume":"94","author":"Paik","year":"2002","journal-title":"J Natl Cancer Inst"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_983_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:32:17Z","timestamp":1787067137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_983_20"}},"subtitle":["A multicenter proficiency ring study"],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_983_20","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}